INCB161734

INCB161734 is a small-molecule drug developed by Incyte. Its target is KRAS (the sponsor names KRAS G12D). The sponsor states: An oral tablet identified on the trial page as a KRAS G12D inhibitor, evaluated in combination with standard chemotherapy (mFOLFIRINOX or GemNabP) versus chemotherapy alone in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07522073 (A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma), in pancreatic ductal adenocarcinoma. The largest, NCT07522073, plans to enrol 588 participants with primary completion expected 2028-09-15. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.